5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer by Jodrell, D I et al.
5-fluorouracil (5FU) is the drug most commonly used in the treat-
ment of patients with colorectal cancer. However, 5FU is active
only during S-phase of the cell cycle and therefore its activity may
be limited by its short plasma half-life in man. Indeed, response
rates in patients with advanced colorectal cancer using bolus
schedules of 5FU are very poor (10–15%) and attempts have been
made to improve this by modification of the schedule of admin-
istration. A response rate of 30% has been achieved using a pro-
tracted venous infusion (PVI) schedule (Lokich et al, 1988) at a
standard dosage (300 mg m22 day21) and this mode of administra-
tion is well tolerated in terms of toxicity. A recent meta-analysis of
1219 patients included in 6 randomized trials also supports the use
of infusional 5FU compared to bolus 5FU (Meta-analysis Group in
Cancer, 1998). 
The plasma concentration of 5FU at steady state (5FU Css)
during PVI 5FU has been reported as being highly variable (<25–
>25 000 ng ml21) and it has also been suggested that this correlates
with the incidence of toxicity (Findlay et al, 1996). However, Findlay
et al reported data from only 19 patients and therefore the phase II
clinical study reported here was designed to further investigate this
issue. Relationships between 5FU exposure and outcome have been
reported for patients with head and neck cancer. Santini et al reported
2 sequential cohorts of patients in whom dose modification was
made based on 5FU exposure (Santini et al, 1989). Santini suggested
an increase in therapeutic index as patients appeared to suffer less
toxicity and the complete response rate was also improved. However,
this was a non-randomized study and differences in the tumour stage
of patients in the 2 cohorts, may have explained the differences in
outcome. Subsequently, a prospective randomized trial has been
performed and in this trial, although survival was no different
between the arms, the utility of monitoring 5FU exposure to reduce
toxicity was confirmed (Fety et al, 1997). 
A relationship between 5FU dose intensity and therapeutic
response has been described in patients with colorectal cancer by
Gamelin et al (1998). In this study, 5FU dosage was optimised
using pharmacokinetic monitoring. This was a phase II trial incor-
porating 152 patients, and this strategy was associated with a high
response rate (43%) and a median survival of 19 months. This trial
did not have a standard therapy control arm, but did appear to
show some association between 5FU concentration and outcome.
An additional factor regulating 5FU pharmacokinetics is circadian
variation (Harris et al, 1990). Analysis of 5FU concentrations
during continuous infusion therapy, identified 11 am as the time of
peak 5FU levels and this was inversely related to leucocyte DPD
activity, where trough activity levels were seen at 11 am in the
same patients (Harris et al, 1990). 
Therefore, the aims of this study were i) to confirm the antitu-
mour activity of PVI 5FU, ii) to document the toxicities associated
with PVI 5FU, iii) to assess the variability in 5FU Css within
the study population and iv) to correlate pharmacodynamic end-
points, such as antitumour activity and toxicity, with the 5FU Css
in individual patients. 
METHODS 
Patients were recruited from the combined Colorectal Cancer
Clinic at the Western General Hospital (WGH), Edinburgh, UK.
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To be eligible, patients had to have a histologically proven diag-
nosis of colorectal cancer which had relapsed following primary
surgery or was advanced (metastatic disease) at the time of
presentation. Patients had to be capable of understanding the
nature of the trial and gave written informed consent. The
protocol had been reviewed and approved by the Lothian
Research Ethics Committee (1702/95/4/20). Patients must have
received no prior chemotherapy for metastatic disease and had
adequate performance status (CTC grade 0–2). Patients had
adequate renal function as assessed by serum creatinine ≤120 mM
or calculated creatinine clearance ³60 ml min-1 and liver function
tests (bilirubin, transaminases) were within the WGH laboratory
normal range, unless associated with metastatic disease. The
patients’ life expectancy was at least 3 months and all patients
were aged ³18 years. The dose of 5FU was 300 mg m22 day21.
This was administered via a skin tunnelled catheter on an outpa-
tient basis using a portable infusion pump. Treatment was
continued for 26 weeks in the absence of dose-limiting toxicity
(DLT, see below) or evidence of disease progression. Patients’
measurable disease was reassessed at 12 weeks to assess tumour
response. In this study, DLT was defined as: CTC grade III
leucopenia (WBC ≤ 2.0 3 109 l21), CTC grade II thrombocy-
topenia (platelets ≤ 75 3 109 l21), any CTC grade II non-haemato-
logical toxicities (unless; nausea and vomiting controlled by
anti-emetic therapy or diarrhoea controlled by loperamide). Any
CTC grade III toxicity resulted in the immediate discontinuation
of PVI 5FU. PVI 5FU could be recommenced following resolu-
tion of DLT, but the administered dose was reduced by 20%.
Toxicity was assessed using standard CTC criteria where applic-
able. Hand–foot syndrome was classified using: 
Grade 0 None 
Grade 1 Mild erythema, pain, dysaesthesias, and/or
oedema; minimal fissures. Does not interfere
with daily living 
Grade 2 Moderate erythema, pain, dysaesthesias,
and/or oedema; moderate fissures. Interferes
with daily living 
Grade 3 Severe erythema, pain, dysaesthesias, and/or
oedema; Ulceration, necrosis or desquama-
tion. Toxicity incapacitating
Blood sampling for 5FU pharmacokinetics 
Plasma 5FU concentration was measured weekly to allow the
assessment of both inter- and intra-subject variability. ALL
samples were taken between 10.00 and 12.00 to minimize the vari-
ation due to circadian rhythm (Harris et al, 1990) and any samples
recorded as being outwith the 10.00–12.00 time period were
discarded. Blood samples were placed on ice immediately and
spun within 15 minutes (Sorvall benchtop centrifuge, 3000 rpm
for 5 minutes). The plasma fraction was then collected and frozen
at -40˚C until the HPLC analysis was performed. 
HPLC analysis of 5FU 
The HPLC assay used was a modification of that of Seymour et al
1994. 300 mg ammonium sulphate was added to 0.5 ml plasma, to
precipitate plasma protein. 5 ml of a mixture of diethyl ether:
propan-2-ol (80/20, %v/v) was added and the tubes were vortexed.
The organic phase was back-extracted using 500 ml of 0.05M
dipotassium hydrogen orthophosphate (pH 10.7). The solution was
mixed and the supernatant discarded. 100 ml of the aqueous phase
was transferred to a mini-Eppendorf and acidified with 20 ml of
1M orthophosphoric acid. 50 ml of this extract was injected onto
the HPLC (Waters 2690 Alliance System, Waters 490E detector). 
A 2 cm pre-column of Spherisorb Octadecyl Silane (ODS),
10 mm, was followed by a 15 cm analytical column of Apex ODS,
5 mm. 0.05 M potassium dihydrogen orthophosphate was used as
the mobile phase with the pump set at a flow rate of 1.0 ml min21
and the column kept at 35˚C. Detection was at 270 nm, run time
was 7 minutes, with a 5FU peak retention time of approximately
3.8 minutes. The limit of quantification was 20 ng ml-1. Day-
to-day interassay variability was 5% and intra-assay variability at
100 ng ml-1 was 6%. 
Simulation of PK data for a similar population of
patients 
The model of 5FU pharmacokinetics described by Seymour et al
(1994) was used to simulate 58 data sets for ‘patients’ receiving
the PVI 5FU schedule at a dose of 300 mg m-2. This model
assumes a single compartment with linear and non-linear elimina-
tion processes, parameterised using Vd (mean = 10.4 ± 1.91 m-2),
Kel (mean = 0.0725 ± 0.0167 min21), Vmax (mean = 0.394 ±
0.126 mg l21 min21) and Km (‘fixed’ = 1.95 mg l21). The
simulation was performed using ADAPT II (D’Argenio and
Schumitsky). 
RESULTS 
Patients and characteristics 
64 patients were entered into the study between July 1995 and July
1997. Of these, 3 were deemed ineligible on review of radiology
(2 patients, no measurable disease) or subsequent pathology/clin-
ical review (1 patient) which was more suggestive of a gastric
primary tumour. All 61 eligible patients (male, 39; female 22)
have completed treatment and the median follow up is 19.3
months. Patients were aged between 33 and 78 years (median 61
years). Performance status was good (PS 0, 49%; PS 1, 43%; PS 2,
8%) in most patients. Liver metastases were present in 51/61
patients (84%) and represented the only site of metastatic disease
in 26 (43%). 
PVI 5FU treatment duration varied from 1–26 weeks, with the
median duration = 21 weeks and 24 patients (39%) achieving
the full 26 week of intended therapy. Reasons given for discontin-
uation of treatment were disease progression, 26 (43%); toxicity,
9 (11%); completion of planned therapy, 24 (39%). There was
1 early death, attributed to 5FU cardiotoxicity, and 1 patient
discontinued therapy due to worsening chronic obstructive
airways disease. 20 patients (33%) required dose reduction for
toxicity at some point during their treatment course. 
Response and survival data for the study population
In the 61 eligible patients, formal radiological assessment of
response took place following 12–13 weeks of therapy and was
only repeated at the end of planned treatment (26 weeks), unless
clinically appropriate. Objective complete (1 patient, assessed by
ultrasound only) or partial responses were recorded in 16/61
patients (26%, 95% CI 16–38%). There have been 52 deaths in
the study population and the median survival for the population602 DI Jodrell et al
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was 11 months. 26 of the 61 patients entered (43%) were alive at
1 year. 
Toxicity 
The PVI 5FU regimen was generally well tolerated, although 47%
of patients required delay and/or dose reduction due to toxicity.
Dose reduction occurred on 31 occasions and these were attributed
to hand–foot syndrome on 19 occasions (61%), diarrhoea on 5
occasions (16%) and stomatitis on 2 occasions (6%). The overall
incidence of toxicities is shown in Table 1. Treatment was discon-
tinued in 4 patients (7%) following Hickman line complications;
thrombus (2), pain or accidental removal by the patient. 
Plasma pharmacokinetics of 5-FU 
5FU pharmacokinetic data at the initial 5FU dose were available
from 58 patients (3 patients discontinued treatment at 300 mg m-2
day -1 before reassessment; 1 due to early dose reduction, 1 due to
rapid disease progression and 1 death due to myocardial
ischaemia). The median number of samples/patient was 8 (range
1–23). The absolute range of concentrations was 30–260 ng ml-1.
The mean 5FU Css was calculated for each patient whilst
receiving full dose (300 mg m-2 day-1) and used for comparative
purposes. This value is referred to subsequently as ‘5FU300Css’.
The distribution of 5FU300Css is shown in Figure 1. 
Although there was some INTER-patient variability (mean;
94 ng ml-1, SD 25, coefficient of variability (CV) = 27%), this was
much less than had been predicted from the data of Findlay et al
when the study was initiated. The degree of INTRA-patient vari-
ability was not excessive (CV; 5–39% (mean = 20%)) in the
majority of patients. However, in 1 patient there was extensive
course to course variability: 5FU Css range 88–260 ng ml21
(mean = 157, n = 10). 
The results from the simulation performed were similar to those
measured: simulation mean = 88 ng ml21 (range 45–240 ng ml21);
measured 94 ng ml21 (range 30–260 ng ml21). 
Relationships of 5FU concentration, patient
characteristics and outcome. 
Outcome measures such as response and toxicity were compared
to 5FU300Css. This allows comparison between patients as it
excludes the impact of duration of therapy and dose reductions on
correlative analyses. Survival was analysed by 5FU concentration,
divided into quartiles, but this did not show any statistically signi-
ficant advantage for higher 5FU concentrations. 
Results (selected) of these analyses are shown in Table 2. In
addition, it was also noted that stomatitis occurred more
commonly (P < 0.003) in women. Previously, it has been reported
that DPD activity is 15% lower in women (Etienne et al, 1994) and
this might lead to a gender difference in plasma 5FU concentra-
tions, as described by Vokes et al (1996). Also, in the Vokes study,
higher 5FU concentrations were associated with an increase in
mucositis. However, in our study mucositis was not related to 5FU
concentration and there was no difference between males and
females in relation to plasma concentrations (P = 0.5156). Indeed,
other authors (Lu et al, 1993) have reported higher DPD enzyme
activity in women. Clearly more work is required in this area. In
addition, in our study, males appeared more likely to respond, but
this is difficult to explain and has not been reported previously. It
is possible that these apparent relationships may represent artefacts
of multiple testing. 
Analyses were also performed using total exposure to 5FU over
time, but this did not provide additional information compared to
the data for 5FU300Css, shown in Table 2. 
DISCUSSION 
PVI 5FU activity in patients with metastatic colorectal cancer has
been confirmed. The overall response rate was 26% and the
median survival was 11 months. The response rate in the original
phase III trial of this regimen was 30% (Lokich et al, 1988) and in
the recently published overview, the response rate for PVI 5FU
was 22% (Meta-Analysis Group in Cancer, 1998). PVI 5FU was
generally well tolerated, although more than half the patients
(52%) required at least 1 break during the 26 weeks of therapy and
20 patients (33%) required a dosage reduction. 
The pharmacokinetic data presented are consistent with pre-
viously published data. In the simulation presented, a population
mean 5FU300Css of 88 ng ml21 was predicted (94 ng ml21 in
our data set) and the predicted range of concentrations, 45–
240 ng ml-1 (compared to 30–260 ng ml21). This comparison also
demonstrates the applicability of the Seymour model to patient
data generated using an alternative method of 5FU administration.
In contrast, in an early paper, Harris et al reported lower 5FU Css
Table 1
Toxicity Percentage of patients at each CTC grade (n = 61) 
01 23 4  
Stomatitis 35 42 18 5 0
Hand/foot 20 43 22 15 N/A
Diarrhoea 32 32 25 12 0
Hickman complications 22 33 40 5 N/A 
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Figure 1 Mean 5FU300 Css per patient 
Table 2
Independent variable Dependent variable P value 
5FU300Css Diarrhoea 0.164 
5FU300Css Hand–foot 0.410 
5FU300Css Stomatitis 0.949 
5FU300Css Dose reduction 0.941 
5FU300Css Tumour response 0.182 5FU pharmacokinetics in colorectal cancer 603
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values (27.4 ± 1.3 ng ml21) at 11 a.m. in patients receiving PVI
5FU at this dose. However, only 7 patients were included in that
study (Harris et al, 1990). 
The inter-subject variability in 5FU300Css (CV = 34%) in this
study is, considerably less than that reported by Findlay et al
(1996). The data of Findlay et al require some discussion as the
range of concentrations they reported was particularly large.
Indeed, the higher concentrations were higher than those reported
for much more intense 5-FU administration protocols (Gamelin
et al, 1998). Questions could be asked about the PK sampling and
subsequent sample handling, although the authors were careful to
state that plasma sampling was not from the Hickman line
explaining the high concentrations and that there was no apparent
delay in freezing and spinning samples to explain the low concen-
trations. Etienne et al (1995) have drawn attention to the mechan-
ism of action of pump devices as most deliver multiple small
boluses and the temporal relationship between these dosing
‘surges’ and sampling, may add imprecision to PK data. However,
intrapatient variability, which might in part be explained by fluctu-
ations in the rate of drug administration, was relatively small in
our study. 
In summary, the activity of PVI 5FU in patients with metastatic
colorectal cancer was confirmed (RR = 26%) and the regimen was
generally well tolerated. Intrasubject variability in 5FU300Css was
not excessive (mean CV = 20%) and was less than inter-subject
variability in 5FU300Css (CV = 27%). Inter-subject variability was
considerably less than that reported by Findlay et al. The lack of
any correlation between 5FU300Css and measures of outcome
suggest that measurement of 5FU concentrations should not be
used to individualise dosing in patients receiving PVI 5FU for
advanced colorectal cancer. 
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